Home Menu

Site Navigation



Parkinson's Disease Tulip


advertisement
NeuroTalk Support Groups > > >

ceregene

Reply
 
Thread Tools Display Modes
Old 05-28-2013, 11:49 PM #1
girija girija is offline
Member
  
Join Date: Nov 2006
Location: southern tip of west coast
Posts: 582
15 yr Member
girija girija is offline
Member
 
Join Date: Nov 2006
Location: southern tip of west coast
Posts: 582
15 yr Member
Default ceregene
Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study



Read an additional analysis of Ceregene Inc.’s gene therapy, which may potentially respond better in people diagnosed within five years prior to treatment:



http://online.wsj.com/article/PR-CO-...googlenews_wsj
girija is offline   Reply With QuoteReply With Quote

advertisement
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
Ceregene CERE-120 Tupelo3 Parkinson's Disease 11 05-02-2013 01:00 PM
ceregene update girija Parkinson's Disease 4 12-18-2011 03:52 AM
Ceregene update... Debi Brooks Parkinson's Disease 2 07-09-2009 01:43 AM
Ceregene's experimental treatment olsen Parkinson's Disease 1 12-09-2006 12:47 AM
Ceregene lou_lou Parkinson's Disease 0 10-13-2006 07:47 AM


All times are GMT -5. The time now is 12:21 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home